Clinical Trial Diversity: User Fee Bill Wants FDA’s Assessment Of Whether It Needs More Authority
Executive Summary
HHS is to evaluate the need for FDA authority to mandate postapproval studies or postmarket surveillance if sponsors do not meet diversity enrollment goals. By contrast, the DEPICT Act would have given the agency the authority to do so.
You may also be interested in...
Clinical Trial Diversity Action Plans Required Under US Funding Bill
Omnibus legislation requires FDA to issue guidance documents and hold public workshops on clinical trial diversity, but it does not give the agency authority to mandate postmarketing studies if a preapproval trial falls short of demographic diversity goals.
Sponsors Want Answers On Consequences Of Missing US FDA Trial Diversity Goals
No negative actions have been taken in the US FDA’s oncology review divisions, but vague diversity guidance continues to raise concerns.
Curb Your Enthusiasm For Continued Use Of Pandemic Clinical Trial Flexibilities, US FDA Says
Even though many approaches were successful, the agency may need a couple years to determine if the data generated were actionable.